Cannabis Use Disorder

Escalate immediately when cannabis use accompanies psychosis, mania, suicidal thinking or behavior, severe agitation, delirium, marked cognitive change, or inability to maintain personal safety. Establish the timing of last use, escalation in frequency or THC exposure, and onset of psychiatric symptoms; obtain collateral history when the patient cannot provide a reliable timeline. In patients with psychotic or mood disorders, temporal correlation between exposure and symptom onset, collateral information, and toxicology can improve diagnostic attribution, but toxicology cannot by itself establish intoxication or causation. PubMedPubMedCannabis Use Disorder - StatPearls - NCBI Bookshelf - NIH

Do not label psychotic symptoms as cannabis-induced solely because cannabis is detected. Continued cannabis use is associated with incident psychotic symptoms, and cannabis exposure is associated with psychosis risk and psychosis relapse; these associations warrant a low threshold to assess for a primary psychotic disorder, bipolar disorder, other substance exposure, and medical causes when symptoms persist beyond the expected exposure window or predate cannabis escalation. BMJ+1BMJContinued cannabis use and risk of incidence and ...BMJBalancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

Use targeted rather than routine laboratory testing. Metabolic, hepatic, infectious, or other testing is appropriate when psychosis, cognitive change, or systemic illness suggests an alternative diagnosis; routine laboratory panels are not required for an otherwise straightforward CUD evaluation. PubMedPubMedCannabis Use Disorder - StatPearls - NCBI Bookshelf - NIH

Diagnose CUD when at least 2 of 11 DSM-5 criteria occur within 12 months. The criteria assess withdrawal, tolerance, larger or longer use than intended, unsuccessful efforts to cut down, excessive time obtaining or using cannabis or recovering from its effects, reduced activities, continued use despite physical or psychological harm, role impairment, hazardous use, craving, and continued use despite interpersonal problems. Severity is mild with 2-3 criteria, moderate with 4-5, and severe with 6 or more. PubMedPubMedConstruct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use

Begin with a brief screen when time is limited, then complete a criterion-level interview after a positive result. The three-item Cannabis Use Disorder Identification Test Short-Form (CUDIT-SF), using a cutoff of 2, demonstrated sensitivity of 78.26%-78.31% and specificity of 76.70%-78.00% for DSM-5 CUD in U.S. and Australian samples. The screen should trigger assessment, not substitute for diagnostic confirmation. PubMedPubMedPreliminary Development of a Brief Cannabis Use Disorder Screening Tool: The Cannabis Use Disorder Identification Test Short-Form - PMC

At the diagnostic visit, quantify past-year and recent use by days per week, amount per occasion, route, product potency when known, time of first use, escalation pattern, motives, withdrawal symptoms, prior quit attempts, and consequences at work, school, home, relationships, finances, and driving. A positive screen warrants assessment of frequency, dose, route, potency, motives, and functional effects. PubMedPubMedCannabis Use Disorder - StatPearls - NCBI Bookshelf - NIH

Use biologic testing selectively. Cannabis toxicology can document exposure, but a negative result does not exclude use and quantitative levels are unreliable for determining intoxication, tolerance, or CUD severity. Do not use a positive urine test as proof that cannabis caused psychosis, vomiting, anxiety, cognitive impairment, or an accident. PubMedPubMedCannabis Use Disorder - StatPearls - NCBI Bookshelf - NIH

Adolescents require a lower intervention threshold. Cannabis exposure during adolescence is associated with greater acute behavioral and cognitive effects than in adults, and adolescent use is associated with later CUD and higher rates of adult mental health disorders, particularly depression and schizophrenia. Counsel adolescents against cannabis use and involve family-based supports when clinically appropriate. Nature+1NatureConsequences of adolescent drug use | Translational PsychiatryWolters KluwerACOG Clinical Consensus No. 7: The Use of... : Obstetrics & Gynecology

For patients with a psychotic disorder, clinical high-risk state, or prior cannabis-associated psychosis, make reduction and cessation a central relapse-prevention target. Cannabis use is associated with psychosis in adolescents and adults, and continued use has been associated with incident psychotic symptoms; high-potency and frequent exposure have been linked to greater adverse psychiatric risk. BMJ+2BMJBalancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studiesBMJContinued cannabis use and risk of incidence and ...NatureCannabis use and glutamate across the psychosis spectrum: in vivo evidence from 7T proton magnetic resonance spectroscopy | Molecular Psychiatry

In pregnancy, screen without stigma, assess for CUD and co-occurring substance use, counsel cessation, and offer behavioral treatment support. Meta-analytic evidence links prenatal cannabis exposure with low birth weight, small-for-gestational-age birth, preterm delivery, neonatal intensive care admission, and other adverse outcomes, although the umbrella review rates this evidence as low certainty. BMJ+1BMJumbrella review of meta-analyses of randomised controlled ...Wolters KluwerACOG Clinical Consensus No. 10: Cannabis Use... : Obstetrics & Gynecology

Ask every patient with ongoing use about driving and other safety-sensitive tasks. Cannabis use is associated with increased motor-vehicle crash risk, and acute THC-related impairment can include impaired perception, motor skills, short-term memory, and somnolence. Advise patients not to drive or operate hazardous equipment while impaired. BMJ+1BMJumbrella review of meta-analyses of randomised controlled ...Wolters KluwerACOG Clinical Consensus No. 7: The Use of... : Obstetrics & Gynecology

Set a patient-specific initial goal: abstinence is appropriate when cannabis use is driving psychosis, hazardous behavior, pregnancy-related risk, major functional impairment, or repeated inability to control use; reduction may be an engagement step for patients not ready for abstinence. Translate the goal into measurable targets such as cannabis-free days, no driving after use, elimination of use before work or caregiving, and attendance at scheduled treatment sessions. Functional and contextual assessment should guide individualized management. PubMedPubMedCannabis Use Disorder - StatPearls - NCBI Bookshelf - NIH

Offer structured psychosocial treatment rather than relying on advice alone. Motivational enhancement therapy combined with cognitive behavioral therapy (MET-CBT), contingency management based on abstinence, and contingency management based on attendance have been evaluated in CUD trials and systematic review. The 2025 evidence synthesis assessed abstinence, treatment completion, use frequency and quantity, craving, adverse events, and cost-effectiveness, with certainty varying across comparisons and outcomes. WileyWileyEffectiveness and safety of psychosocial interventions for the treatment of cannabis use disorder: A systematic review and meta‐analysis - Halicka - 2025 - Addiction - Wiley Online Library

Use motivational interventions to resolve ambivalence, then use CBT to identify triggers, develop alternative responses, and plan for high-risk situations. For patients with repeated nonresponse, severe CUD, marked role impairment, co-occurring psychiatric illness, or other substance use disorders, increase visit frequency and integrate addiction and mental health care rather than treating each condition sequentially. CUD treatment is often complicated by co-occurring mental health and other substance-use disorders. Nature+1NatureCannabis use and cannabis use disorder | Nature Reviews Disease PrimersWileyEffectiveness and safety of psychosocial interventions for the treatment of cannabis use disorder: A systematic review and meta‐analysis - Halicka - 2025 - Addiction - Wiley Online Library

Do not present N-acetylcysteine (NAC) as established pharmacotherapy for CUD. A preliminary 8-week trial in cannabis-dependent adolescents and young adults reported greater odds of negative urine cannabinoid tests with NAC 2,400 mg/day plus behavioral therapy than with placebo plus behavioral therapy, but this remains adjunctive and investigational rather than standard treatment. ScienceDirectScienceDirectN-acetyl cysteine in the treatment of cannabis use disorder: A systematic review of clinical trials - ScienceDirect

Document the diagnostic basis as: cannabis products and route; frequency and escalation; last use; DSM-5 symptom count and severity; withdrawal and craving; psychiatric symptoms; other substance use; hazardous activities; pregnancy status where relevant; functional consequences; patient-stated goals; and the treatment plan. This separates exposure, disorder severity, acute risk, and response monitoring. PubMed+1PubMedConstruct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance usePubMedCannabis Use Disorder - StatPearls - NCBI Bookshelf - NIH

For patients in whom cannabis may be contributing to psychosis or mood instability, document the symptom-use timeline and collateral source. This preserves diagnostic uncertainty appropriately while supporting a concrete plan for cessation-oriented care, psychiatric monitoring, and reassessment if symptoms persist. PubMed+1PubMedCannabis Use Disorder - StatPearls - NCBI Bookshelf - NIHBMJBalancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies